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IFN-␣ has a direct antiproliferative effect on both normal and CML progenitor cells in vitro, but no selective anti-leukemic activity on progenitor cell proliferation has been demIntroduction onstrated. 16, 17 It is possible that therapeutic responses to IFN-␣ can be identified by the relative intracellular levels of IRF1 Type I interferons (IFN-␣ and IFN-␤) are cytokines that exert and IRF2, since an IFN-induced increase in IRF1 or decrease antiproliferative activity on normal and transformed cells, and in IRF2 will result in rise in the IRF1:IRF2 ratio which may be are able to block growth factor-stimulated cell cycle trana critical event in the regulation of cell growth. In the present sitions. IFNs are induced by growth factors and viruses, which study we have addressed this question by devising a sensitive suggests that they take part in a feedback mechanism that method for measuring this ratio and analysing its pattern in regulates cell growth. 1 Interferon regulatory factors (IRF) 1 and CML patients treated with IFN-␣. 2 are DNA-binding proteins which control IFN gene expression. 2 The two factors are structurally related, particularly in the amino-terminal region, which confers DNAMaterials and methods binding specificity, and they independently bind to a promoter element shared by the IFN-␣ and IFN-␤ genes, as well
Patients and normal individuals as many IFN-inducible genes. [3] [4] [5] Gene transfection studies have demonstrated that IRF1 funcPeripheral blood (PB) and/or bone marrow (BM) specimens tions as an activator for IFN and IFN-inducible genes, whereas were obtained from 260 CML patients, and from 25 healthy IRF2 represses the action of IRF1. 6, 7 Expression of the two volunteers aged 24 to 56 years, with informed consent as required by the Declaration of Helsinki. The CML series consisted of 227 patients studied at chronic and IFE − (5Ј-ccctGaGGtAGCATgCGGTA-3Ј). As shown in and six Ph-negative patients for BCR gene rearrangement by Figure 1 , these primers were designed to span regions of high quantitative Southern blot. 19 These patients received recombihomology between the two genes; in positions where the two nant IFN-␣2a, b or c, or lymphoblastoid IFN-␣n1, either alone sequences were mismatched, a base (indicated in lower case) or in combination with hydroxyurea, busulphan or cytosine was introduced that was unrelated, ie non-homologous, to arabinoside. IFN-␣ therapy was usually started in the first year either IRF1 or IRF2. Because each primer can anneal equally from diagnosis, with an initial dose ranging from 3 × 10 6 IU to both IRF1 and IRF2 sequences, this is essentially a competi-3 days per week to 9 × 10 6 IU 7 days per week. The dose tive PCR assay in which the relative amount of amplified prowas adjusted to reach leucocyte counts of Ͻ5 × 10 9 /l. duct from each cDNA species provides an estimation of the Cytogenetic response to IFN-␣ was assessed at 12-28
proportional concentration of the RNA transcripts in the test months (median 30 months) after initiation of treatment in all sample. The PCR was set up in 25 l volume containing but 16 patients in whom the response was assessed between 10 mM Tris pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 250 M each 6 and 12 months on IFN. Three of these 16 patients had a dATP, dCTP, dGTP and dTTP, 0.25 M each 5Ј and 3Ј primer, good response within this period. The remaining 13 patients 0.5 U Taq polymerase and 1 l cDNA. All PCR experiments from this group were also included in the analysis, in order included a negative-control reaction without DNA template. to avoid selection of patients who had survived more than 12
Rigorous precautions were taken to avoid the possibility of months on IFN-␣, which would introduce a bias towards the false-positive results, as described elsewhere. 22 Thermocyanalysis of patients with better prognosis. In all but four of the cling conditions were: three cycles of denaturing at 96°C for 91 Ph-positive patients at least 20 metaphases were analysed, 30 s, annealing at 46°C for 50 s, extension at 72°C for 1 min, and the cytogenetic response was defined as: good, comprisfollowed by 30 cycles of denaturing at 96°C for 25 s, ing complete (0 Ph + metaphases) and partial (1-34% Ph + annealing at 60°C for 50 s, extension at 72°C for 1 min, folmetaphases) responses, or poor, including patients with a lowed by a final extension at 72°C for 10 min. Four microliters minor (35-94% Ph + metaphases) and no response (95-100% of reaction products were electrophoresed through ethidiumPh + metaphases). Among the four patients with less than 20 bromide stained 1.5% agarose mini-gel, visualised and photoanalysable metaphases, two had a good and two a poor cytographed under UV light ( Figure 1a ). genetic response. The response status in these four patients was confirmed by molecular analysis (see below), which showed results within the same categories. In Ph-negative Identification of IRF1 and IRF2 transcripts patients response was determined by Southern blot analysis. Absence of the rearranged BCR band was treated as equival-A unique EcoRI site present in the IRF2, but absent from the ent to complete cytogenetic response. Molecular response IRF1 cDNA (Figure 1 ), was used as a restriction fragment was assessed by estimation of the concentration of BCR-ABL length polymorphism (RFLP) to distinguish the amplified trantranscripts and/or of the BCR-ABL:ABL transcript ratio by a scripts from the two genes. Nine microliters of PCR product competitive PCR titration assay as previously described. 20 In were digested with EcoRI in a 15 l reaction (Figure 1b ). Ten the majority of samples the quantitative PCR assay was performicroliter products of the EcoRI digestion were electrophormed contemporaneously with the cytogenetic analysis. The esed through a 2% agarose gel, transferred by Southern blotmolecular response was defined as good (BCR-ABL:ABL ratio ting to a nylon membrane, prehybridized and hybridized at Ͻ14%) or poor (BCR-ABL:ABL у14%) as described else-42°C overnight to the IFCO oligonucleotide probe. This 20-where. 20 mer synthetic oligonucleotide (5Ј-GATCCCAAa/gACa/ gTGGAAGGC-3Ј) is degenerate at the two positions of nonhomology (indicated in lower cases) between IRF1 and IRF2.
Processing of samples
The membrane was washed in 2 × SSC at room temperature and exposed to radiographic film at −70°for 2-8 h. Densito-PB and BM leucocytes from normal individuals and from CML metric analysis of the 290 bp and 201 bp hybridisation bands patients were isolated by red-cell lysis of centrifuged buffy-( Figure 1c ) was done by the NIH Image program. The ratio coat preparations. For some experiments, the leucocytes were IRF1:IRF2 represents the relative intensity of the upper band separated by gradient centrifugation over Ficoll-Hypaque to (IRF1 product) to the lower band (IRF2 product 
Results
genetic responders the IRF1:IRF2 ratio prior to treatment was 0.90 and 5.11, respectively, with the four partial responders exhibiting ratios between 1.05 and 1.56. All the 53 patients
Validation of the assay with minor or no cytogenetic response had initial ratios below 2.5. In order to measure the ratio of IRF1:IRF2 gene expression, we designed an assay system (Figure 1 ) based on RT/PCR coIn a separate series of 226 samples from 97 CML patients studied at various time-points after starting IFN-␣ therapy a amplification of transcripts from both genes, followed by restriction digestion of the PCR products and Southern highly significant correlation was found between the IRF1:IRF2 ratio and the cytogenetic response to IFN-␣ treathybridization with an oligonucleotide probe capable of quantitatively identifying the two cDNA sequences, ie the uncut ment: whereas 46% (53/115) of samples from patients who achieved a good response (Ͻ35% Ph-positive metaphases) IRF1 and the largest of the two digested IRF2 fragments. Densitometric analysis of the scanned autoradiographic images prohad IRF1:IRF2 ratios above 2.0, only 14% (13/91) of those with a poor cytogenetic response (у35% Ph-positive vided an estimate of the level of expression of each gene, as measured in arbitrary units, from which the ratio IRF1:IRF2 metaphases) showed IRF1:IRF2 ratios above 2.0 ( 2 test: P Ͻ 0.0001) (Tables 1 and 2 ). Similarly, there was a highly was derived.
Several experiments were set up initially to test the reprosignificant correlation between the IRF1:IRF2 ratio and the molecular response (ie low ratio of BCR-ABL:ABL transcripts) ducibility and sensitivity of the PCR/RFLP/hybridization assay. These experiments showed that there was little difference in to IFN-␣ therapy in all 199 samples investigated for BCR-ABL:ABL and IRF1:IRF2 ratios simultaneously in the latter serthe IRF1:IRF2 ratio obtained from replicate reactions of the same cDNA sample, as indicated by the low coefficient of ies of patients: 51 out of 106 samples showing good response had ratios above 2.0, as opposed to only 18 out of 93 samples variation (CV) for a seven-replicate assay on eight samples (CV 3, 3, 3, 5, 5, 6, 8 and 11%, respectively). Similarly, six halfshowing poor response (P Ͻ 0.0001; 2 test) ( Table 3 ). In six Ph negative patients, two complete responders had maximum log serial dilutions of the cDNA templates up to 1:1000 did not introduce significant variation in the IRF1:IRF2 ratio (CV IRF1:IRF2 ratios of 5.0 and 8.2, while four poor responders had ratios between 1.5 and 2.0 (Table 1) . Overall analysis of 4, 5, 5 and 9% for four samples).
the 97 CML patients in relation to the highest IRF1:IRF2 ratio achieved after IFN-␣ therapy showed that this was above 2.0 in 30 of the 43 good responders and in only 12 of the 54 poor IRF1:IRF2 ratio in normal and CML specimens responders (Figure 3 ). Five patients were analysed before and during IFN-␣ treatAnalysis of peripheral blood leucocytes from 25 normal individuals showed that the IRF1:IRF2 ratio varied between 1.13 ment. Only one of these patients achieved a complete cytogenetic response: he had a high ratio (5.11) at diagnosis and and 2.30, with a median of 1.35 and a mean ± s.d. of 1.49 ± 0.33 (Figure 2a) . Similar values were obtained for six normal on two other occasions 2 and 5 months after initiation of IFN-␣, but specimens tested at 18 and 24 months showed ratios bone marrow specimens, with no significant difference between granulocytes and mononuclear cells or, among the in the normal range (1.76 and 2.2, respectively). One other patient, who achieved a partial response, had a low (1.11) latter, between CD34 + and CD34 − cells (range of all measurements, 0.86-2.57).
IRF1:IRF2 ratio at diagnosis, high ratios 6 and 12 months after IFN-␣ was started (4.82 and 3.25, respectively), and lower In contrast, the IRF1:IRF2 ratio in leucocytes from CML patients (n = 166) showed a much wider variation (0.53-5.11) ratios in the range 1.13-2.19 on four samples tested subsequently at 15, 16, 17 and 26 months. In each of these two (Figure 2a ). Eleven out of 130 patients in chronic phase had ratios above the normal range, whereas none of the 33 blast patients the respective cytogenetic response was detected approximately 12 months after initiation of IFN-␣ therapy and crisis samples had a ratio Ͼ2.5. (Figure 2b) .
was sustained throughout the follow-up period. The remaining three patients in this group showed no response to IFN-␣ and exhibited low ratios before and throughout or after treatment.
IRF1:IRF2 ratio and response to IFN-␣
It should be noted, however, that for two of the latter patients only one post-IFN-␣ specimen (approximately 24 months after Analysis of diagnostic specimens from 59 CML patients treated with IFN-␣ showed that in the two complete cytoinitiation of therapy) was available for tests. 
Table 3
Comparison patients are heterogeneous and that, in some cases, IFN-␣ administration does not control the disease. Early identifi-2 test P Ͻ 0.0001.
cation of these patients would therefore be useful, as it would avoid the need for a long-lasting, expensive and potentially toxic therapy, and accelerate the administration of alternative Overall, no obvious correlation was observed between the IRF1:IRF2 ratio and time on IFN-␣ or changes in IFN-␣ dose forms of treatment. Conversely, detection of patients who are likely to benefit significantly from IFN-␣ could justify the in patients for whom multiple follow-up samples could be analysed. Similarly, we did not detect significant numbers of decision to include this drug as a first-choice treatment for a longer period of time. patients with persistently high ratios. Thus, whereas most of the good responders had high IRF1:IRF2 ratios on at least one The gradual unravelling of the IFN-␣ signalling pathways provides a biological framework for investigating the variaoccasion (Figure 3) , earlier or later samples from the same patients could be found with ratios in the normal range.
bility of clinical responses to IFN-␣ treatment in CML. In the present study we focused on the possibility that deviations in either the steady-state or in the induced mRNA levels of the antagonistic transcription factors IRF1 and IRF2 could dictate responsive patients, IFN-␣-induced overexpression of IRF1 by
